Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Leukemia through trial conditions or approval indications mapped to it or to one of its descendant entities.
26 drugs · 856 active trials
42 drugs · 1,287 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 14 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Melphalan | Phase 3 | Phase 3 | 32 | 15 | 8 | 148 | 0 | — | — | 1991-12 |
| Zanubrutinib | Phase 3 | Phase 3 | 22 | 11 | 5 | 27 | 0 | — | — | Jun 29, 2016 |
| Leucovorin | Phase 3 | Phase 3 | 19 | 5 | 27 | 87 | 0 | — | — | 1990-02 |
| Sirolimus | Phase 3 | Phase 3 | 13 | 6 | 4 | 65 | 0 | — | — | 1996-03 |
| Ponatinib | Phase 3 | Phase 3 | 12 | 6 | 2 | 36 | 0 | — | — | 2008-06 |
| Omacetaxine Mepesuccinate | Phase 3 | Phase 3 | 10 | 6 | 5 | 27 | 0 | — | — | 1994-09 |
| Selinexor | Phase 3 | Phase 3 | 9 | 2 | 1 | 25 | 0 | — | — | 2014-03 |
| Vorinostat | Phase 3 | Phase 3 | 8 | 2 | 2 | 38 | 0 | — | — | 2000-01 |
| Daratumumab | Phase 3 | Phase 3 | 8 | 6 | 2 | 18 | 0 | — | — | Sep 20, 2016 |
| Sorafenib | Phase 3 | Phase 3 | 7 | 3 | 5 | 35 | 0 | — | — | 2006-07 |
| Nivolumab | Phase 3 | Phase 3 | 7 | 2 | 1 | 33 | 0 | — | — | May 16, 2013 |
| Nelarabine | Phase 3 | Phase 3 | 6 | 3 | 5 | 26 | 0 | — | — | 1997-06 |
| Tisagenlecleucel | Phase 3 | Phase 3 | 6 | 3 | 4 | 22 | 0 | — | — | Mar 17, 2010 |
| Duvelisib | Phase 3 | Phase 3 | 6 | 2 | 2 | 15 | 0 | — | — | 2013-05 |
| Pegfilgrastim | Phase 3 | Phase 3 | 5 | 4 | 1 | 17 | 0 | — | — | 2002-11 |
| Aldesleukin | Phase 3 | Phase 3 | 4 | 4 | 6 | 56 | 0 | — | — | 1992-08 |
| Chemotherapy | Phase 3 | Phase 3 | 4 | 0 | 5 | 21 | 0 | — | — | 1997-02 |
| HyperCVAD Regimen | Phase 3 | Phase 3 | 4 | 3 | 1 | 5 | 0 | — | — | 2010-07 |
| Hydroxyurea | Phase 3 | Phase 3 | 3 | 3 | 9 | 17 | 0 | — | — | 1994-10 |
| Teclistamab | Phase 3 | Phase 3 | 3 | 3 | 1 | 3 | 0 | — | — | Aug 9, 2019 |
| Carboplatin | Phase 3 | Phase 3 | 2 | 1 | 1 | 19 | 0 | — | — | 1991-12 |
| Donor Lymphocyte Infusion | Phase 3 | Phase 3 | 2 | 2 | 1 | 8 | 0 | — | — | 2013-12 |
| Levoleucovorin | Phase 3 | Phase 3 | 2 | 1 | 1 | 2 | 0 | — | — | Aug 8, 2017 |
| Sorafenib Tosylate | Phase 3 | Phase 3 | 1 | 0 | 1 | 13 | 0 | — | — | 2005-06 |
| Guadecitabine | Phase 3 | Phase 3 | 1 | 0 | 2 | 10 | 0 | — | — | Jan 4, 2011 |
| Amsacrine | Phase 3 | Phase 3 | 1 | 1 | 5 | 7 | 0 | — | — | 1986-11 |
| Hematopoietic Cell Transplantation | Phase 3 | Phase 3 | 1 | 0 | 1 | 5 | 0 | — | — | 2001-02 |
| Chemoimmunotherapy | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | Feb 25, 2019 |
| Talquetamab | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | 2026-07 |
| Tipifarnib | Phase 3 | Phase 3 | 0 | 0 | 2 | 22 | 0 | — | — | 1999-06 |
| Carmustine | Phase 3 | Phase 3 | 0 | 0 | 2 | 20 | 0 | — | — | 1991-12 |
| Volasertib | Phase 3 | Phase 3 | 0 | 0 | 1 | 12 | 0 | — | — | Nov 27, 2008 |
| Barasertib | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | 2006-05 |
| Crenolanib | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | 2012-07 |
| Dinaciclib | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | 2006-08 |
| Peginterferon Alfa-2b | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | Oct 22, 1998 |
| Lestaurtinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2003-10 |
| Rigosertib | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2010-07 |
| Lonafarnib | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | Apr 30, 2001 |
| Peginterferon Alfa-2a | Phase 3 | Phase 3 | 0 | 0 | 3 | 3 | 0 | — | — | 2003-09 |
| Interferon Alfa-2b | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Oct 22, 1998 |
| Interferon Alpha-2a | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 1994-09 |
| Dactinomycin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 1996-03 |
| Lomustine | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2008-02 |
| Pixantrone Dimaleate | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2007-08 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.